19 unchanged sentences
Hoppenot holds a Diploma from ESSEC International Business School.
−Removed: Hoppenot is also a director of Cellectis S.A.
−Removed: Dashyant Dhanak , age 62, joined Incyte in December 2018 as Executive Vice President, Chief Scientific Officer.
−Removed: Prior to joining Incyte, Dr.
−Removed: Dhanak served as Vice President and Head of Discovery Sciences of Janssen Research & Development, LLC, a wholly-owned subsidiary of Johnson & Johnson, a pharmaceutical company, from 2013 until November 2018.
−Removed: Prior to his tenure at Janssen, Dr.
−Removed: Dhanak spent 25 years at GlaxoSmithKline, a pharmaceutical company, in positions of increased responsibility across multiple disease areas, including his last position as Vice President and Head of the Cancer Epigenetics Discovery Performance Unit.
−Removed: Dhanak received a B.S.
−Removed: in Chemistry from the University of Manchester Institute of Science and Technology and his Ph.D.
−Removed: from the University of London.
−Removed: He completed his postdoctoral research in natural product synthesis at Northwestern University.
+Added: Cagnoni, age 60, joined Incyte in June 2023 as President and Head of Research and Development.
+Added: From November 2022 to May 2023, Dr.
+Added: Cagnoni served as Chief Executive of Laronde (now Sail Biomedicines), a Flagship Pioneering Company, and Executive Partner at Flagship Pioneering.
+Added: Prior to joining Laronde and Flagship, he served as President and Chief Executive Officer of Rubius Therapeutics, Inc., a biotechnology company, from June 2018 until November 2022.
+Added: From May 2015 until June 2018, Dr.
+Added: Cagnoni served as President and Chief Executive Officer of Tizona Therapeutics, Inc., a privately held biotechnology company.
+Added: Cagnoni previously served as President of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, from October 2013 to April 2015 and Executive Vice President, Global Research and Development and Technical Operations from March 2013 to October 2013.
+Added: Prior to Onyx, Dr.
+Added: Cagnoni was Senior Vice President and Global Head of Clinical Development at Novartis Oncology from October 2009 to March 2013.
+Added: From 2007 to 2009, Dr.
+Added: Cagnoni was Senior Vice President and Chief Medical Officer at Allos Therapeutics (acquired by Spectrum Pharmaceuticals) and, prior to that, Chief Medical Officer of OSI Pharmaceuticals (acquired by Astellas Pharma Inc.).
+Added: Cagnoni received an M.D.
+Added: from the University Buenos Aires School of Medicine, and completed post-doctoral work in Hematology and Oncology at the Mount Sinai Medical Center, New York, and in Stem Cell Transplantation at the University of Colorado Health Sciences Center.
+Added: Sheila Denton , age 58, joined Incyte in October 2023 as Executive Vice President, General Counsel and Corporate Secretary.
+Added: Denton most recently served as Senior Vice President, General Counsel and Corporate Secretary of Boehringer Ingelheim USA, Inc., where she was responsible for the legal, compliance and policy teams for the human health, animal health and biopharmaceutical businesses.
+Added: During her 19-year tenure with Boehringer Ingelheim, Ms.
+Added: Denton held a number of other key leadership positions both in the United States and abroad, in multiple areas such as acquisitions, the generic businesses, and litigation.
+Added: Prior to joining Boehringer Ingelheim, Ms.
+Added: Denton was a partner in a New England-based law firm.
+Added: Denton received her J.D.
+Added: from Western New England College School of Law, and her B.S.
+Added: in Business and Political Science from Sacred Heart University.
Dickinson , age 56, has served as Executive Vice President and General Manager, Europe, since June 2019 and joined Incyte as Senior Vice President and General Manager, Europe in June 2016.
14 unchanged sentences
Flannelly earned his doctorate in pharmacy from the University of Maryland, School of Pharmacy, his master’s degree in business administration from the University of Baltimore, and his B.S.
−Removed: degree in Pharmacy from Massachusetts College of Pharmacy.
+Added: in Pharmacy from Massachusetts College of Pharmacy.
Vijay Iyengar , age 51, joined Incyte in May 2016 as Executive Vice President, Global Strategy and Corporate Development.
3 unchanged sentences
Iyengar received his B.S.
−Removed: degree in Biology from Stanford University and earned his M.D.
+Added: in Biology from Stanford University and earned his M.D.
from Harvard Medical School.
6 unchanged sentences
in Physics and Applied Mathematics from the University of London, United Kingdom.
−Removed: Pasquale , age 57, joined Incyte in April 2018 as Executive Vice President and General Counsel.
−Removed: Prior to joining Incyte, Ms.
−Removed: Pasquale joined Incyte from Celgene Corporation, a biopharmaceutical company, where for 17 years she held positions of increasing levels of responsibility, including Chief Counsel;
−Removed: Senior Vice President, Legal and Deputy General Counsel and Assistant Corporate Secretary, and, most recently, Executive Vice President and Global Chief Compliance Officer.
−Removed: Prior to her tenure at Celgene, Ms.
−Removed: Pasquale spent a decade supporting pharmaceutical clients as a global patent and litigation attorney at Pennie & Edmonds LLP in New York (now part of Jones Day).
−Removed: Before her career in law, Ms.
−Removed: Pasquale was an Assistant Research Scientist at the Institute for Basic Research and the Cold Spring Harbor Laboratory.
−Removed: Pasquale holds a J.D.
−Removed: from Brooklyn Law School and a B.S.
−Removed: in biochemistry from the State University of New York at Stony Brook.
Christiana Stamoulis, age 53, joined Incyte in February 2019 as Executive Vice President and Chief Financial Officer.
26 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.